ArticleClinical ophthalmology (Auckland, N.Z.)2025
Influential Factors and Outcome of High-Risk Keratoplasty in a Tertiary Referral Corneal Center: A Retrospective Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Topical Tacrolimus (FK506) in High-risk Penetrating Keratoplasty: A Systematic Review and Meta-analysis of Comparative Studies.Eye (London, England) · 2025Pooled it
- Icariin alleviates corneal neovascularization by regulating inflammation through inhibition of macrophage polarization and the NF-κB pathway.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Corneal allograft survival is dramatically decreased in high-risk (HR) host beds. The purpose of this study was to investigate the outcome of HR keratoplasty (KP) in a single-center tertiary referral clinic and to determine risk factors for graft failure. Methods: This retrospective study included adults referred for HR penetrating KP between 2014 and 2022. HR criteria were history of re-KP, stromal neovascularization in ≥2 quadrants, and signs of significant inflammation/manifest perforation at the time of surgery. The primary endpoint was graft failure within the first postoperative year. Donor endothelial cell count, donor age, stromal neovascularization, and manifest perforation/acute inflammation at surgery were independent variables in the univariate/multivariable logistic regression. Results: Graft survival 1 year after surgery was 56.2% (CI: 45.7, 66.4), 68.3% (CI: 59.3, 76.4), and 70.2% (CI: 56.6, 81.6) after the first, second, and third KP, respectively. The presence of perforation/acute inflammation at baseline was found to be an independent factor statistically significantly associated with graft failure. Graft failure occurred in 190 (51%) of 375 KPs in 257 patients during overall observation. The median time (95% CI) from KP until graft failure was 559 (392, 994) days for the 1 Conclusion: Acute inflammation/perforation at the time of surgery were the major risk factors for graft failure in HR KP. Reduced survival rates for HR KPs were confirmed in this study, which highlights the need for further developments in the treatment of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.